Outpatient Treatment for Late Stage Cancer
Cancer is just an ailment, we treat it like one
Efficient
Fast acting and effective treatment course allows patients to receive effective treatment in any cancer stage and recover within weeks of receiving treatment
Environmental
With the elimination of chemotherapy supplies, we reduce the global radioactive pollution caused by mishandling of the toxic waste that are disposed
Universal
Proprietary Nano-technology allows use of one treatment type for multiple types of cancer, lowering overall costs for patients and establishments
Current therapeutic strategies for advanced-stage cancers, particularly non-small cell lung cancer (NSCLC), suffer from significant limitations including off-target effects, treatment resistance, and tumor microenvironment (TME) adaptability. OscilloBeam Therapeutics presents an integrated dual-modality nanoplatform that synergistically applies magnetic hyperthermia and photothermal therapy. This system is designed for tumor-selective activation using externally controlled magnetic fields and near-infrared (NIR) light, offering a non-invasive, localized, and scalable approach to tumor ablation.
Despite notable progress in oncology, stage III/IV solid tumors—especially in NSCLC and related metastatic profiles—continue to present low survival rates due to resistance to immunotherapy, limited treatment options, and insufficient therapeutic specificity. As tumor cells adapt to immune pressure and evolve drug resistance, there is an urgent need for novel therapeutic frameworks capable of targeting tumors physically rather than solely relying on biochemical suppression. OscilloBeam Therapeutics proposes a physics-driven platform designed to exploit thermally-induced apoptosis through controlled magneto-photothermal therapy (MP-TT), potentially overcoming the core limitations of both systemic chemotherapy and immunotherapy in resistant cancer cases.
Lean and simple design
“Don’t fix it if it ain’t broke” is often overlooked. Simplest solutions are the best solutions.
Simulation-Driven Nanotechnology for Accelerated Medical Breakthroughs
Leveraging advanced simulation and computational modeling to optimize, and validate novel Nano-materials for challenging applications prior to extensive lab work, we have significantly reduced R&D timelines and costs for partner companies.
Market Share and Growth
With a current US market of $377BN, and exponential forecasted cancer treatment market potential, the investment criteria have never looked better.
Featured Articles
Let’s work together to eradicate cancer
Learn how you can be a part of our team, regardless of your time constraints